Pfizer, CDM clean up at Doctors' Choice Awards

Share this article:
Professional ads for Pfizer's Chantix and Organon's NuvaRing were the year's top-rated as judged by physicians in the Association of Medical Media's fifth annual Doctors' Choice Awards.
The two-page Chantix ad, executed by Euro RSCG Life LM&P, was the top-scoring ad in the general practice category, while the one-page NuvaRing ad, by CommonHealth's Adient, took top honors in the specialty category.
The survey, which drew responses from 6,040 physicians, included 332 professional ads in 11 therapeutic categories among the 200 most widely advertised products for 2006.
Pfizer was the year's big winner with a total of five awards – for top scoring one- and two-page ads as well as the highest-ranked ads within the cardiovascular and anti-infective categories. Genentech/OSI, Merck and Organon each took two awards. On the agency side, Cline Davis & Mann was tops with four awards – three for Pfizer and one for Novo Nordisk's Novolog Flexpen -- while AbelsonTaylor, Euro RSCG Life LM&P and CommonHealth's Adient each won two.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...